APL-102 / Apollomics - LARVOL DELTA

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress (GlobeNewswire) - "Other pipeline programs : (i) APL-122:...Edison has completed six dose escalation cohorts in the Phase 1 trial, including two within the expected therapeutic window, and expects to provide a data update in 2025; (ii) APL-102:...The Phase 1 clinical trial in China has been closed and Apollomics expects to provide topline results in 2025."

P1 data • Trial status • Solid Tumor

Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria (clinicaltrials.gov) - P=N/A | N=15 | Recruiting | Sponsor: Children's Hospital of Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Metabolic Disorders • Phenylketonuria • Rare Diseases

Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria (clinicaltrials.gov) - P=N/A | N=15 | Not yet recruiting | Sponsor: Children's Hospital of Fudan University

New trial • Metabolic Disorders • Phenylketonuria • Rare Diseases

APL-102 Capsule in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Apollomics Inc.

New P1 trial • Oncology • Solid Tumor

Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102 (GlobeNewswire) - “Apollomics Inc…announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics of APL-102 delivered via an oral capsule.”

Trial status • Oncology • Solid Tumor

Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study (GlobeNewswire) - “Apollomics, Inc…announced that APL-102 has received China Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the initiation of a Phase 1 pharmacokinetic (PK) and tolerability study of APL-102 in patients with advanced solid tumors.”

Non-US regulatory • Oncology • Solid Tumor